Skip to main content
Quest Diagnostics

White paper - Accelerating alzheimer’s therapy innovation

Neurology Center of Excellence White Paper

Accelerating alzheimer’s therapy innovation: The power of blood-based biomarkers

The escalating global challenge of Alzheimer's Disease (AD) demands new approaches to detection, diagnosis, and treatment. 

 

This whitepaper is free and can be downloaded and read at your convenience.

doctor with blood tube labeled with Tumor marker for analysis of cancer biomarkers test. Blood tube for Study of Tumor Marker test in biochemistry lab. Generative AI

Join healthcare professionals, researchers, and thought leaders in exploring this pivotal frontier.

Stay ahead of the curve and leverage the insights to shape strategies, interventions, and future

Our latest white paper, "Accelerating alzheimer’s therapy innovation: The power of blood-based biomarkers," delves into recent advancements in the AD diagnostic landscape.

Discover how blood-based biomarkers are reshaping AD therapy by:

  • Simplifying diagnosis: Uncover the non-invasive, painless procedures that are making early detection more accessible

  • Promoting early intervention: Explore how blood-based tests enable proactive measures, even before symptoms appear

  • Facilitating longitudinal monitoring: Learn how continuous tracking of disease progression paves the way for personalized therapeutic strategies

  • Boosting cost-effectiveness: Find out how this accessible approach is more economically viable, promoting widespread adoption

This comprehensive paper delves into the critical role of blood-based biomarkers in the diagnosis and treatment of Alzheimer's disease (AD). It explores the global impact of AD, examining the prevalence and societal challenges, and underscores the urgent need for early detection and intervention. 

The paper also outlines Quest Diagnostics pioneering work in AD diagnostics, including the innovative AD-Detect™ Amyloid Beta 42/40 Ratio test, and presents a detailed comparison of blood-based testing with traditional imaging and CSF methods. With a focus on accessibility, cost-effectiveness, and patient care, it paints a vivid picture of how blood-based biomarkers are reshaping the field of neurological diagnostic testing and accelerating Alzheimer's therapy.

 

Don't Miss Out on the Future of AD Therapy

Access the white paper now and embark on a journey into the transformative power of blood-based biomarkers in Alzheimer's therapy innovation.

655

* indicates required

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.